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Venous disease will affect 1-3% of the western world at some point in their lives, yet 
there are few effective treatments for the venous system [1]. One such disease is chronic 
venous insufficiency (CVI), a painful and debilitating illness that affects the superficial 
and deep vein valves of the legs. When the valves become incompetent they allow reflux 
and subsequent pooling of blood. Current clinical therapies are only moderately; and 
therefore, the need for a better solution remains. 
 
Prosthetic venous valves were constructed from a novel hydrogel biomaterial patented by 
Georgia Tech. The valves had flexible cusps similar to normal, anatomic venous valves. 
The purpose of this work was to evaluate the thrombotic potential of the GT venous valve 
in an in vitro study and to design a percutaneous delivery system. In vitro thrombosis 
model provides an appropriate intermediate step between valve development and in vivo 
analysis, which is necessary to determine the biocompatibility of the prosthetic device. 
 
The flow system was modified from a one-pass, flow-through thrombosis assay using 
whole blood [2] to mimic pulsatile physiologic conditions. Cessation of flow indicated 
thrombotic obstruction. Histological analysis was performed using H&E staining and 
Carstair’s stain (specific for platelets). A group of valves were lined with Dacron to 
confirm the thrombotic potential of the system.  All Dacron valves were occluded by 
thrombus connecting the polymer fibers with adherent platelets. 
 
Whole blood perfused through the GT prosthetic valves exhibited no thrombosis or 
platelet adherence.  All GT valves were patent and competent after blood perfusion.  
H&E staining revealed no thrombus deposition on the GT vein valves. 
 
 xiv
A percutaneous delivery system was designed after evaluating the GT valves for their 
compressibility and plastic deformation over time. Appropriate stents, catheters and 
sheaths were selected. As designed, this system will be utilized in an ovine trial of the 
valve. Due to the low in vitro thrombotic potential and strong history of PVA as a 
medical implant material, positive trial results are expected. With successful animal and 
human trials this valve can provide a potential intervention for the 7 million people 





The venous system was identified in 335BC when Praxagoras of Cos differentiated 
arteries from veins [3]. Andrea Visalius accurately depicted the venous anatomy in 1543 
[3]; Fabricus elaborated on these findings in 1603 (Figure 1), followed by Harvey in 1628 
[4] who identified the direction of blood flow and the concept of circulation with 
experimental reasoning. Carrel and Guthrie reported the first autotransplantation of 
animal valve-bearing vein segments in 1906 [5]. Twenty-three years later, Franklin 
described the anatomy of venous valves in 1929 [6, 7]. Surgical techniques were then 
largely neglected until 1947 when Johns then studied venous anastomosis [8]. Shortly 
after in 1953, Eiseman and Malette reported the first technique of valve reconstruction in 
the canine inferior vena cava by constructing a valve out of the vessel wall [9]. Venous 
valve autotransplantation was performed in the dog by De Weese and Niguidula in 1960 
[10]. The first venous valve repair in man was pioneered by Kistner in 1968 [11]. The 
first vein valve autotransplant was reported by Taheri et al. in 1982 [12]. The venous 
system was first identified in 335BC, yet to this day vascular surgeons rarely operate in 
the venous system, and life threatening complications continue. 
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Figure 1: Illustration of Vein Valves from the Fabricus Atlas, 1603 
 
Vein Anatomy and Physiology 
Vein Anatomy 
The leg venous system has three venous networks, deep veins, superficial veins, and 
perforating veins (Figure 2). The deep veins are of large diameter and lie deep beneath 
the muscles of the leg and close to the bones. The deep venous system starts as the tibial 
vein near the calf, turns into the popliteal vein near the knee, progresses into the femoral 
vein located in the thigh, and finally becomes the iliac vein prior to emptying into the 
inferior vena cava. The superficial venous system consists of small diameter veins that 
are found just below the surface of the skin, and perforating veins connect the superficial 
veins to the deep veins.  
 
 3
      
Figure 2: (Left) Deep Veins of the Leg, (Right) Posterior Superficial and Perforation veins of the Leg 
[13] 
 
Each venous network contain one-way vein valves; though the anatomic structure, 
location, and number of valves varies among individuals. The most common venous sites 
are the common femoral vein, just above the entrance of the long saphenous, and in the 
superficial femoral just below the profunda femoris. The typical location and number of 
valves in the leg is found in Table 1. The distal vessels contain the greatest number of 
valves to decrease the pressure exerted by each valve. The anatomic structure varies from 
one to five leaflets; however, the valves generally are bi-leaflet. The thickness of leaflets 
varies from 20 to 50 microns. When blood is flowing the leaflets distend to provide an 
opening area of about 35% of the full luminal area [14]. The muscle pressure on the 
vessels distort the veins to have an elliptical cross-section. The leaflets are composed of 





Table 1: Average occurrence of valves in deep veins [15] 
Deep Vein # of 
Valves 
Common Femoral Vein (above sapheno-femoral junction) 1 
Femoral Vein (below sapheno-femoral junction) 3 
Popliteal Vein 1 
Posterior Tibial Vein 19 
Anterior Tibial Vein 11 
Peroneal Vein 10 
 
Vein valves have been classified as either ostial valves or parietal valves. Ostial valves 
are located where a smaller vein branch meets a larger vein, they aid in distribution of 
blood throughout the leg during leg muscle contractions. Parietal valves are generally 
positioned in the larger vessel proximal to a venous junction. Parietal valves are the main 
pressure-bearing valves and are therefore more critical to CVI. 
 
Vein walls are comprised of 3 layers, intima, tunica media, and adventitia. The intima is 
the inner most layer and is in contact with the blood, it is composed of elastic media. The 
tunica media is the middle layer and is a more complex structure consisting of its own 
three layers. Starting from the inside the first layer is composed of longitudinal muscle 
fibers, elastin fibrils and connective tissue. The middle tunica media contains bundles of 
smooth muscle cells separated by elastic fibrils. The outer tunica media comprises 
longitudinally oriented muscle bundles and fibrous tissue. The vein outer layer is the 
adventitia, which contains connective tissue, nerve fibers, and vasa vasorum. 
 5
Vein Valve Physiology 
Vein valve activity is random and sporadic. During any static activity, such as standing or 
sitting, the valve cusps are open and the pressure in the foot is equal to the haemostatic 
pressure exerted by the column of blood from the foot to the right atrium. When a leg 
muscle contracts the intramuscular vein pressure drops to zero, the venous valves will 
then close preventing reflux. Venous valves are most active during rhythmatic activity, 
such as walking or exercising.  
Venous Pumps 
The leg contains 3 venous pumps, calf, thigh and foot, which play a vital role in returning 
venous blood to the heart. The calf pump is the most important because it generates the 
highest pressure (200 mm Hg) during muscular contraction, the resting venous pressure is 
approximately 100 mm Hg and reduces to 30 mm Hg after 10 or more repetitive calf 
contractions. Abnormalities in the valves can impede or negate the function of the calf 
pump; this results in ambulatory venous hypertension, which is an inability to reduce the 
superficial venous pressure. 
Vein Mechanical Properties 
Veins are highly distensible at low pressures, and distention ceases when intramural 
pressure reaches approximately 50 mm Hg, with diameter expansion limited to 1.5 to 1.6 
times the original vein diameter [16, 17]. The distentions of the veins help minimize 
trauma to the vein, improve comfort for the patient, and reduces the risk of inflammation 
or thrombus formation in the immediate valve area. 
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Chronic Venous Insufficiency 
 
Chronic Venous Insufficiency (CVI) is a disease that causes symptoms in the leg 
including swelling, edema, pain, itching, varicose veins, skin discoloration, ulceration 
and limb loss [18]. Post-thrombotic damage within the deep veins is the most significant 
cause of CVI. Thrombus formation permanently damages veins by adhering to the vein 
wall and becoming permanent when the thrombus organizes, becoming replaced by 
fibrous tissue and covered by a neoendothelium. Thrombus arising in the valve pockets or 
coming in direct contact with valve cusps irreparably damage their function. Permanent 
endothelialized strands of residual organized thrombus (synechiae), may develop across 
the vein wall, obstructing outflow or binding the valve leaflets to the vein wall [13]. An 
illustration of competent and incompetent vein valves is shown in Figure 3. Another 
possible cause of valve leaflet deterioration is fibrinolysis. Fibrinolysis is typically 
referred to when plasmin is degrading the fibrin and thrombus; however, in the case of 
CVI, plasmin may also be degrading the delicate valve leaflets [13]. Even though DVT is 
the most common precursor to CVI, approximately two-thirds of patients with venous 
insufficiency give no history of DVT [19-21].  
 
Reflux is also not always indicative of CVI, as about 15% of normal limbs have reflux in 
the common femoral vein. Normal limbs often show incompetence, which is limited to 
the superficial femoral valves. A strong indicator of CVI is incompetence in the popliteal 
vein and the deep calf veins. Strong indicators of ulcer development are incompetent 
distal superficial veins [19, 21]. Patients with persistent valvular reflux develop chronic 
venous hypertension (venous pressure above normal range) and ambulatory venous 
pressure (the blood pressure inside veins while walking above normal range). Venous 
hypertension causes leakage of red blood cells and macromolecules (i.e. fibrinogen and 
α2-macroglobulin) into the dermal interstitium. The initial chronic inflammatory signal 
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responsible for leukocyte recruitment is the RBC degradation products and interstitial 
protein extravasation which act as chemoattractants to the leukocytes. A cascade of 
pathologic events follows, resulting in dermal fibrosis. 
 
 
Figure 3: (Left) Competent and patent valves, and (Right) obstructed and incompetent valves 
 
Chronic venous insufficiency can typically be diagnosed as either primary or secondary 
incompetence. Other causes of chronic venous insufficiency exist and are mentioned 
below.  Primary incompetence is the degradation of a valve due to aging, whereas 
secondary incompetence is caused by a damaging obstruction in the vein. Primary 
incompetence is more common, though may progress into secondary incompetence. 
Patients with secondary incompetence are the primary candidates to receive surgical 
interventions. 
 
Primary incompetence develops as the structural composition of veins change. As 
humans age their vein walls naturally distend as the elastic fibers and muscle layers 
become disorganized. Another symptom of aging includes the elastic lamina of the intima 
layer becoming fragmented, atrophic, thin, and irregular [22]. 
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As vein walls progressively distend due to primary incompetence the veins become 
vulnerable to high-pressure distention and thrombus formation. Valve damage can be 
caused by distention to the point where the valve leaflets no longer meet in the lumen, 
and/or thrombus formation in the leaflet pockets caused by unnatural turbulence and 
stagnation areas in the vein [23]. These incompetent leaflets over time will fold over and 
be absorbed into the vein wall. Secondary incompetence is when the vein valves are lost 
[24]. The incidence of secondary incompetence in patients with ulcerations and deep 
venous reflux has been reported as high as 95% [25]. 
 
The physiological consequences of venous incompetence depend on the location of the 
incompetent valve(s). The combination of competent perforating veins, a powerful calf 
pump and the absence of obstruction can compensate for deep venous valvular 
incompetence. Perforating veins inevitably become incompetent as they act as safety 
valves for incompetent deep veins, allowing blood under high pressure in the calf pump 
to escape. Intervention is necessary when the perforating veins become incompetent and 
the calf pump no longer compensates. 
 
The absence of one vein valve results in increased pressure to the distal valve. Similar to 
the initial incompetent valve the distal valve will experience distention and abnormal 
blood flow regions. This distal valve will likely become incompetent and the disease will 
cascade down the leg. 
 
Other processes that lead to valvular incompetence and CVI involve vascular trauma, 
tumor growth, and deep vein thrombosis (DVT). Patients with a history of DVT have 
over a 25-fold increase chance for developing CVI compared to patients without a history 
of DVT [26]. 
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Risk factors of CVI include heredity, obesity, pregnancy, a sedentary lifestyle, smoking, 
or being female over 50 years of age. A patient suffering from CVI may have a rash on 
the skin of the calves or ankles (indicative of lipodermatosclerosis), reddened or 
discolored skin on the leg, edema or swelling, ulceration or skin breakdown, or varicose 
veins. An extreme clinical case of venous incompetence is depicted in Figure 4; this 
patient has swelling, brownish discoloration, a tough hardened area at the ankle, and 
ulceration.  
 
Figure 4: Patient with an extreme case of venous incompetence 
 
 
Diagnosis of CVI is typically accomplished by identifying the signs and symptoms. 
Anatomic studies are intended to identify the location of incompetent valves for severe 
cases which will involve invasive surgery, like venous venotomy or valve transplantation. 
CVI imaging techniques are explored further below. Valves that are typically addressed 
surgically are the upper superficial femoral vein or popliteal vein. Surgical options are 




Phlebography (also called venography, ascending contrast phlebography, or contrast 
phlebography) is an invasive diagnostic test that provides an image of leg veins on a 
fluoroscope screen [27]. It is the standard for identifying and quantifying reflux in 
individual veins. The fluoroscope images allow for identification of the location and 
condition of vein valves and blood clots, and the overall condition of the veins.  
The widespread availability and noninvasiveness of duplex Doppler, color Doppler and 
compression ultrasound has reduced the need for contrast phlebography in venous disease 
diagnosis; but phlebography is the "gold standard," and the best test by which other 
imaging methods are judged [28]. Venography is essential for patients who are 
considered for valvuloplasty or valve substitution, as it is the most accurate test for 
detecting vein valve incompetence and vein thrombosis. It is nearly 100% sensitive 
(probability of a positive test among patients with disease) and specific (probability of a 
negative test among patients without disease) in making this diagnosis. Accuracy is 
crucial since deep vein thrombosis and CVI are potentially fatal conditions. 
Descending phlebography, first established by Bauer in 1948, provides a method to 
identify vein valve sites and to study their degree of competence [29]. The patient is 
positioned on a fluoroscopic table inclined to a minimum of 60˚. The contralateral 
common femoral vein is typically chosen as the site of venipuncture, although a brachial 
or antecubical approach are alternatives. Contrast is injected during a forced Valsalva 
maneuver. A Valsalva maneuver is an effort to exhale without letting air escape through 
the nose or mouth. Heparin (5000 units) is intravenously administered prior to 
catheterization. The examined leg is non-weight bearing. Reflux is observed under 
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fluoroscopy and graded according to the classification of Kistner and associates [30]. 
Videotaping for post-procedure evaluation is a common practice, a competent vein valve 
imaged with descending venography is presented in Figure 5. 
 
 
Figure 5: Descending venogram of a competent vein valve [13] 
 
The risk associated with phlebography is a reaction to iodinated contrast. The contrast is 
an irritant to the intima which causes thrombosis in 1-2% of cases [31]. False-positive 
interpretations are possible, owing to the relatively high density of the contrast medium, 
which may trickle down the relaxed leg through normal but partially open valves. 
Ambulatory Venous Pressure 
Ambulatory venous pressure provides a general measurement for venous insufficiency. 
Pressure measurements are obtained by placing a needle in the foot and having the patient 
perform maneuvers. A normal patient will have pressures between 0-20 mmHg, someone 
with incompetence will have elevated pressures. Venous obstruction, valvular reflux and 
calf muscle pump failure cannot be separately identified with this method. This test has 
been replaced by non-invasive alternatives due to its invasive procedure. 
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Duplex Scan 
Duplex scanning is a noninvasive test that is the most clinically useful test for detecting 
the location of venous valves, and evaluating venous valvular incompetence and chronic 
venous obstruction [13]. Duplex scanning incorporates a pulsed-Doppler flow-velocity 
detector; which confirms the presence or absence of flow indicates the direction of flow, 
and records flow patterns. The addition of a color-coded flow map allows immediate 
identification of arteries and veins. Blood flowing towards the heart is depicted as blue 
(indication of veins), and red for blood flowing towards the peripheries (indicating 
arteries). Encroachment or absence of flow is easily detected. Color is helpful to 
immediately identify reflux. Duplex scanning has a sensitivity between 82-87% and a 
specificity between 92-99% [32, 33].  
 
Duplex scanning depicts the vein over a relatively long region and will show multiple 
vessels simultaneously; these benefits eliminate the need to interrogate the leg every 
centimeter (which is necessary with CW Doppler). In contrast, venograms provide an 
even larger image region. 
 
Veins are identified by their characteristic audible Doppler signal and velocity spectrum 
(or color-flow map). The probe is adjusted to provide a long-axis view of the segment of 
interest. The patient is then asked to perform a Valsava maneuver to reverse the normal 
pressure gradient. Competent valves will prevent retrograde flow by valve closure, where 
incompetent valves will permit retrograde flow. Retrograde flow is indicated by an 
inverted spectrum, or by a change in the flow-map color from blue to red. A reflux flow 
longer than 1.0 seconds is considered abnormal. 
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An alternative method to quantify valvular incompetence involves the patient in a 
standing position, a pneumatic cuff is positioned around the leg about 5 cm below the 
transducer site, and the cuff is inflated to 80-120 mm Hg (depending on cuff location) for 
about 3 seconds [34]. Normal valves close rapidly when the cuff is deflated in response to 
temporary flow reversal. In 95% of competent veins, reflux flow is less than 0.5 seconds; 
therefore, retrograde flow greater than 0.5 seconds indicates valvular incompetence; in 
most cases incompetence reflux is about 3-4 seconds. This technique has proven to be 
more sensitive than the supine-manual compression or Valsalva methods [35]. 
 
Valves can be identified on duplex scanning by their geometry, as healthy sinuses have 
an elliptical configuration and the leaflets are thin and mobile, Figure 6 illustrates venous 
valve geometry. Diseased valve sinuses are distorted, may contain echogenic material, 
and the thick and short leaflets are rarely visible. Many duplex instruments permit the 
diameter of the vein to be measured, the machine can then determine the mean flow rate 
by multiplying the reflux flow velocity by the cross-sectional area. Locating the valves is 
clinically desirable, though is not always possible, due to their degenerated state and the 
echogenicity of the blood. 
 
 
Figure 6: Stereo Microscope Image of a Venous Valve (Magnification of x 11.2), the left image is a 
distal view, the right image is a proximal view [13]. 
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Continuous-Wave Doppler 
Continuous-wave Doppler (CW Doppler) is an older technology than Duplex scanning, 
though it may provide sufficient information if Dupplex scanning is not available. CW 
Doppler inversely relates the frequency of the transmitted ultrasound to the sonic 
penetration. To evaluate deep veins a low frequency around 5 MHz is used, and for 
superficial veins a higher frequency of 10 MHz is used. Examinations are performed with 
the patient relaxed and comfortable in a slightly inclined supine position of 10-15˚ 
(Trendelenburg position). The initial step is to locate the corresponding artery (easily 
identified by direction of flow) and to shift the probe towards the vein. The common 
femoral, superficial femoral, popliteal and posterior tibial veins can all be identified. Care 
must be taken to apply minimal external probe pressure to prevent the veins from 
collapsing. Compressing the leg below the probe displaces blood up the leg; thereby, 
increasing the Doppler audible signal. Compressing the leg above the probe restricts 
venous outflow causing blood to back up in the veins below the site of compression, upon 
relief of compression the blood rushes up the leg. If the probe is shifted more than a 
centimeter from the corresponding artery then the vein is likely not to be patent.  
 
Valvular incompetence can be demonstrated by reversal flow in the vein. The patient 
performs a Valsava maneuver where the intra-abdominal pressure is increased; thereby, 
forcing blood out of the inferior vena cava and iliac veins. Competent valves will prevent 
retrograde flow by valve closure, where incompetent valves will permit retrograde flow. 
It is important to note that one competent valve proximal to the probe will prevent reflux 
and may lead to a false-negative result. To minimize a false negative the common 




CW Doppler demonstrates a sensitivity to identify incompetence of 73% in the saphenous 
vein, 33% in the lesser saphenous, and 48% in the deep veins [36]. CW Doppler has 
specificity of 90%. More accurate tests, like venography and duplex scanning, are more 
commonly used. 
Plethysmography  
Plethysmography is a noninvasive test that measures volume displacement in a limb 
segment. An air filled plastic sleeve is typically placed around the calf, the patient is then 
asked to perform a series of maneuvers, and the pressure in the pneumatic sleeve 
monitors the change in limb volume. The volume is recorded by a pulse volume recorder 
(plethysmograph) that measures the pulse waves from each cuff. Plethysmography may 
be performed as a basic diagnostic test, prior to more in depth alternatives. 
 
Plethysmography provides quantitative information for venous outflow obstruction, 
valvular incompetence, and calf muscle pump function [13]. For obstructions the rate of 
volume change in an elevated limb is measured. The volume-measuring device is 
positioned around the calf and the pneumatic cuff is placed around the thigh. The leg is 
elevated above the heart and the venous flow is occluded by inflating the cuff to 60-80 
mmHg. Blood volume accumulates, stabilizes and then the cuff is rapidly vented. The 
output trace compared against normal values is used to determine obstruction. Valvular 
incompetence using plethysmography involves placing the transducer distally on the leg. 
Measurements are conducted by having the patient perform a calf exercise followed by a 
relaxation period; refill times are recorded and compared against normal values to 
determine incompetence. Slow refill times indicate incompetent valves. Calf muscle 
pump function is evaluated with air plethysmography by comparing the percentage of 
venous volume ejected by the calf against the percent venous volume which cannot be 
 16
expelled. Plethysmography accurately quantifies CVI and is therefore a common test 
used to support venography. 
 
Surgical Repair of Incompetent Venous Valves 
Historically, surgical treatment was avoided due to lack of accurate surgical technology 
and the extreme risk of post-operative thrombosis. Through the advancement of 
diagnostic imaging, surgical technology, and anticoagulation, the clinician’s options for 
addressing venous disease has greatly increased over the past 40 years; however all 
procedures are extensively time consuming and extreme cases are only pursued 
surgically. Invasive venous valve repair or replacement techniques are reserved for 
patients with a congenital absence of functional valves and severe cases of DVI. An 
evaluation is conducted, including a complete history and physical examination, 
assessment of the clinical status [37], and imaging with duplex ultrasound and 
plethysmography.  
 
The first venous surgical technique was ligation of grossly incompetent veins by Linton 
in 1938 [38]. Ligation is the stripping of superficial vessels and does not address the 
problem of deep venous incompetence. Ligation was the only surgical treatment until 
Kistner, in 1968, developed the technique of internal valvuloplasty [11], as illustrated in 
Figure 7. The current surgical procedures for deep venous incompetence include 




Figure 7: Longitudinal Venotomy and Valve Repair [13] 
 
Valvuloplasty 
The standard of care in the surgical correction of primary reflux is a valvuloplasty. This 
surgical procedure involves a venotomy, where the valve cusps are plicated 20-25%; a 
PTFE sleeve is often placed around the operation site to maintain valve integrity, as 
illustrated in Figure 8. Kister who pioneered this technique, omitting the PTFE sleeve, 
concluded that one competent vein valve in the deep-venous system of the leg at the 
femoral level would reverse abnormal hemodynamics [40]. Further reports have indicated 
that reversing abnormal hemodynamics is more complicated and that repair of the most 
proximal valve in the superficial femoral vein is only sufficient when the profunda 
femoris vein is competent [41, 42]. In these rare cases a valvuloplasty has a 60% success 
rate over 5 years [43]. A singular valvuloplasty has shown not to be valid for systems that 
include occlusion of the femoral or popliteal vein, or absence/incompetence of the 





Figure 8: Placement of PTFE sleeve as a support following a venotomy [13] 
 
 
Johnson demonstrated in 10 patients that venous valve refilling time can be temporarily 
improved by repair of the femoral valve [44]. Unfortunately this valve repair failed to 
demonstrate improvement in pressure or venous refilling times in 12 to 18 months post 
operation. They concluded that repair of the femoral valve alone does not cure chronic 
venous inefficiency, and the ineffective calf communicating veins contribute to this 
inefficiency. 
 
In another study, 125 extremities with reflux in the greater saphenous and superficial 
femoral veins were followed for 7 to 8 years [45]. Surgical procedures included 
phlebectomy and Kistner’s Technique [40]. Phlebectomy is a surgical technique 
involving stripping of the greater saphenous vein with stub avulsion of varicose 
tributaries. Their results indicated that disease was aggravated in 24% of extremities, 
though 92% of the corrected valves demonstrated clinical improvement. They concluded 
that surgical correction of the incompetent superficial femoral vein valve would change 
the course of primary chronic venous insufficiency. 
 
A large study of 582 venous valve reconstructions in 347 limbs was performed from 1979 
to 1994, by Raju, S. and Hardy, J.[43]. This study provided a collection of venous 
operational techniques and evaluation parameters for determining venous valve surgery 
success. Patients were selected for surgery once conservative therapy failed or recurrent 
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complications developed. Those selected for surgery experienced primary reflux (55%), 
post-thrombotic reflux (39%), and congenital dysplasia (6%). The valves were evaluated 
based on 4 measurable parameters. These parameters included restoration of valve 
competence, maintenance of patency without hemodynamic stenosis, healing without 
damage to the repaired valve due to hematoma or infection, and rapid resolution of stasis 
ulceration after surgery. Postoperative duplex examination showed competence in 78% of 
valves, with 16% partially competent and 6% reflexive. The femoral valve repair for 
primary valve reflux was successful in 60% of cases over 5 years. Deep venous thrombus 
developed in 3% of valves. Stasis ulcers were common, occurring in 267 limbs, though 
rapid healing occurred in 93% of these ulcers. This study concluded that an internal 
valvuloplasty is ideal for repair of a single valve in the leg, though this procedure is time 
consuming and is therefore impractical for multiple valve reconstructions. A popular 
alternative to valvuloplasty is the transcommissural technique (described below), which 
combines the benefits of both open and closed techniques, and it is rapidly becoming the 
first choice for valve repair.  
 
The transcommissural valve repair is performed by placing transluminal sutures along the 
valve attachment lines, which simultaneously closes the valve attachment angle and 
tightens the valve cusps [46]. Raju, Berry, and Neglan reported in 2000 the repair of 141 
limbs after 30 months of follow up with duplex Doppler ultrasound. Complications arose 
in 9% of limbs, including: infection, hematoma, seroma, thrombosis, and embolus. Post-
operatively the valves were competent in 78% of limbs, and at 30 months 59% were 
competent. They concluded that transcommissural valvuloplasty is safe with a low 
morbidity. Compared to internal valvuloplasty, it is a fast and simple procedure, small 
veins can be repaired, and multiple valves can be addressed in a single stage. 
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Advances in venotomy include external valvuloplasty, and angioscopic-assisted 
valvuloplasty [47]. The external valvuloplasty is performed without the use of a 
venotomy; it places the placating sutures from outside the lumen to tighten the 
commissural angle. The angioscopic-assisted valvuloplasty uses an angioscope that is 
introduced through a side branch and advanced into the proximal SFV, it is then 
positioned directly above the valve. Blood is cleared from the field by irrigation. Through 
use of a video-enhanced, magnified angioscopic visualization, sutures are passed from 
outside to inside the lumen. These techniques lessen vessel trauma and reduce the 
dependence of anticoagulants. Unfortunately, when the valve apparatus is completely 
destroyed, limited options are available; they include axillary vein transfer and de novo 
valve reconstruction. 
Vein Segment Transposition 
When a normal functioning vein valve is in close proximity to the incompetent vein 
valve, a vein segment transposition procedure may be performed, as illustrated in Figure 
9. The incompetent vein is dissected, mobilized, and transposed on to the normal vein 
distal to a functional valve. As CVI cascades down the leg the distal vessel is often also 
afflicted. The long term patency rate for transposed valves is 17-66% [48]. 
 




Vein Valve Transplantation 
A vein valve transplantation is performed by mobilizing a valve containing vein segment 
from either the axillary or brachial veins and transplanting it into either the popliteal or 
femoral vein systems, as illustrated in Figure 10. Allograft and cadaveric vein 
transplantations are not common practices due to the low quantity of suitable donor 
valves, and the negative immunogenic response. 
 
Valve transplant can cause unnecessary trauma to the patient’s leg, and most procedures 
require indefinite post-operative anti-coagulation.  Therefore, transplantation is used only 
when alternative methods have failed, such as medication, physical rest, therapy, and 
other less invasive surgical procedures. Problems arise even prior to surgery because it is 
difficult to find a suitable donor valve. This is evidenced by the fact that 30 to 40% of 
axillary vein valves, which are often used for superficial femoral venous valve 
replacement, are found incompetent prior to harvesting [49].  The long term patency rate 
for transplanted valves is 17-66% [48]. 
 
 
Figure 10: Vein Valve Transplantation [13] 
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Cryopreserved Human Vein Valves 
Cryopreserved human vein valves result in high morbidity (48%), poor patency (41% 
patent at 24 months), poor competency (27% competent at 24 months) and poor clinical 
results [50]. Furthermore, ulcers reoccurred in 50% of patients, pain relief was 
dissatisfactory, and swelling was not improved. It was found that nearly three-fourths of 
the cryopreserved valves required some transcommissural repair prior to implantation. 
The poor performance of cryopreserved valves was attributed to the effects of 
cryopreservation on structural integrity and the immunogenic response elicited after 
implantation [50]. 
 
Prosthetic Vein Valves: Animal Studies 
 
Several animal trials to test prosthetic venous valves have been performed since 1985. 
Canine (dog) was the most common animal used prior to 1995, and since the animal 
models were swine (pig) and ovine (sheep). It is appropriate to assume that the canine 
model was progressively phased out due to the hyperthrombogenic potential of canine 
blood. The lengths of the animal trials were for 1 week up to 8 months. 
 
In 1985, Hill et al. designed implantable venous valves, one set fabricated of 
Pellethane®, a polyurethane elastomer, and others were fabricated from gluteraldehyde-
fixed umbilical cord segments.  They implanted the valves in the external jugular vein 
and contralateral jugular vein of canine for up to eight days. All umbilical vein valves 
were occluded within 48 hours. Two of the eight Pellethane valves were patent at 5 days, 
though all were occluded by 8 days [51]. These valves demonstrated poor patency results. 
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Gerlock et al. implanted Bioprosthetic cardiac valves in the vein valve position, in 1985. 
These valves were trileaflet and constructed from gluteraldehyde-fixed pericardium and a 
Dacron graft. They implanted these valves into the inferior vena cava of four dogs.  Two 
dogs were assessed at six months and two at eight months, all valves were patent at both 
time points [52]. 
 
In 1988, Taheri et al. developed a bi-leaflet mechanical vein valve [53, 54].  They 
performed both in vitro and in vivo experiments on platinum and pyrolitic carbon-covered 
titanium valves.  They implanted the valves in the femoral vein and inferior vena cava of 
10 canine by transverse venotomy. At 3 months, seven of the ten valves remained patent 
and competent.  Those valves that failed resulted in severe thrombotic occlusion. Taheri 
et al further reported in 1995 that after two years, these valves developed dense ingrowth 
of intimal hyperplasia which rendered the valves functionless [55]. 
 
Rosenbloom et al., in 1988, created an autogenous venous valve constructed from canine 
external jugular veins [56]. Fifteen valves were implanted into fifteen dogs. Six canine 
were euthanized immediately after valve placement, six canine were euthanized at 1 
week, and three canine received heparin and were sacrificed within 7 to 13 days. All 
acute animals demonstrated patent and competent valves. Two of six dogs at the 1 week 
time point were both patent and competent, the remaining 4 dogs had complications 
arising to thrombosis. All three valves from the heparin group were patent and 
competent. 
 
Stent based polyetherurethane membrane vein valves were studied in 1993 by Uflacker 
[57]. They implanted the prosthetic valve in the superior and inferior vena cavae of 
swine. The valves exhibited good function at 1 week follow-up on supine and upright 
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cavograms (phlebography on the vena cava). However, partial thrombosis appeared 
inside the valve cusps. 
 
Gomez-Jorge et al. percutaneously delivered eleven glutaraldehyde-fixed bovine external 
jugular vein bioprosthesis mounted on a Nitinol stent into the inferior vena cavae or 
external iliac vein of eleven swine [58]. An acute experiment was performed on seven of 
the eleven animals; the four remaining animals were evaluated for 2 weeks. Deployments 
of the bioprostheses were successful in nine of 11 swine. In the survival group, 2/4 valves 
were patent without evidence of thrombus formation by ascending and descending 
venography. Complications included hemarthrosis, death, and bioprosthesis thrombosis 
immediately after deployment. Histopathologic analysis showed endothelial cells 
covering the luminal surfaces. The wall of the bioprostheses had granulomatous response 
and foreign body reaction. Bacterial contamination was noted in one bioprosthesis. Prior 
to a long-term study, Gomez-Jorge et al. are evaluating the bioprosthesis durability, 
immunogenicity and leaflet function of their bioprosthetic vein valves. 
 
 




The percutaneously delivered venous valve bioprosthesis (PVVB) valve, currently in 
clinical trials, was evaluated in a porcine study during 2003 [59].  The PVVB is a 
glutaraldehyde-preserved bovine jugular valve-bearing venous xenograft sutured inside a 
Nitinol frame, as shown in Figure 12. Nine pigs underwent catheter delivery. One PVVB 
 25
was inserted and deployed in each iliac vein under fluoroscopic control. PVVBs were 
evaluated with phlebography at either 2 or 4 weeks to assess patency and competence; all 
PVVBs were explanted and processed for histological analysis. In 8 animals, the PVVB 
was successfully deployed in both the left and right iliac veins. Four animals were 
sacrificed at 2 weeks, 7 of 8 valves were patent and 3 of 8 were competent. Five animals 
were sacrificed at 4 weeks, 5/10 were patent and 2/10 were competent. Histology showed 
thrombosis as the cause for all non-patent valves. Clinical trials are currently underway; 
they are further discussed under the Clinical Trials heading. 
  
Figure 12: First Generation PVVB [59]. 
 
Bonhoeffer et al. evaluated a fresh bovine vein valve as an option for pulmonary valve 
replacement [60]. Despite the fact that the valve position is different to the vein valves, 
the Bonhoeffer et al. results are discussed to demonstrate a simple in vitro patency and 
competency test that may be performed post explantation. A vein segment containing a 
native biological valve was harvested from a bovine jugular vein and sutured into a 
platinum balloon expandable stent, as seen in Figure 13. Eleven lambs underwent 
catheterization for transcatheter pulmonary valve replacement. The successfully placed 
valves were explanted 2 months after implantation.  Competent and patent valves were 
evaluated by restoring function in vitro after removal of the pannus, as seen in Figure 14. 
For a competent valve, water was flown in the retrograde direction, as seen in Figure 14 
the valve demonstrates effective closure of the valve. To demonstrate patency, water is 
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flown from distal to proximal, again as seen in Figure 14 the valve demonstrates effective 
opening of the leaflets. 
 
 
Figure 13: Fresh bovine jugular vein attached to a platinum stent [60]. 
 
 
Figure 14: In vitro competency and patency test of bioprosthetic pulmonary valves after 2 months in 
vivo. Left, competency test; and right, patency test [60]. 
 
 
Between 2000 and 2005, Pavcnik et al reported on percutaneously delivered vein valve 
prosthesis [61-69].  The valve was constructed from Nitinol or stainless steel wires and a 
sheath of porcine small intestine submucosa (SIS). SIS is an acellular material derived 
from small intestines [62]. Unlike other xenograft tissues which promoted host fibrotic 
tissue grown, SIS tissue promotes host tissue generation specific to the site of 
implantation. The first generation bioprosthesis is shown in Figure 15, and collapsed for 
transcatheter delivery in Figure 16. In 2002, 25 valves were implanted into the external 
jugular veins of 12 sheep. The valves were assessed over a period of 6 months, where 
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88% of the valves demonstrated good long term patency and competency [70]. They also 
reported that host cells integrate into the SIS collagen matrix [68]. All 3 failed valves 
were the result of prosthesis tilting, where one valve thrombosed at one month and the 
other two were patent with moderate reflux at three months. Tilting refers to the valve 
being misplaced and not positioned perpendicular to flow. With these vein valves, a 
clinical trial was performed, the results from this trial are further discussed under the 
Clinical Trials section [64]. 
  
 
Figure 15: SIS vein valve bioprosthesis [67] 
 
 
Figure 16: SIS vein valve bioprosthesis, collapsed for catheter delivery [67] 
 
 
A second generation SIS bioprosthesis (SG-BVV), by Pavcnik et al., was evaluated in 
2004 and 2005 [66, 67]. The revised bioprosthesis included a modified stent from the 
original design to prevent tilting. The second generation SIS vein valves are shown in 
Figure 17, stainless steel and Nitinol versions were designed. Forty-eight prostheses were 
implanted, via catheter delivery, into the jugular veins of 24 sheep. The animals were 
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euthanized at 6 weeks. The prosthesis prevented reflux in 44/48 valves (91.6%) The 
failed valves were the result of stent over expansion and prosthesis over sizing. Pavcnik 
et al indicated that matching valve size with vein diameter is essential for good valve 
function. They suggested that an optimal prosthesis is 10% to 15% undersized. Clinical 








There are currently no commercially available prosthetic vein valves. However, the 
success of the animal trials by Pavcnik et al. and the PVVB study indicate positive 
progress in the prosthetic venous valve industry [59, 67]. Several major achievements 
have developed since the infancy of prosthetic vein valve animal trials; such as, 
standardization of imaging techniques, the choice of more appropriate animal models, 
and the advancement in surgical procedures. Initially venograms were not consistently 
used in animal trials; however, this imaging technique eventually became the standard to 
test for patency at implant and explant. An attractive evaluation technique was performed 
by Bonhoeffer et al. who provided a simple test for in vitro patency and competency. It is 
appropriate to assume that the canine model may be progressively phased out due to the 
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hyperthrombogenic potential of canine blood. Ovine and porcine models have similar 
thrombosis potentials to humans, though they are lower than the canine thrombotic 
potential [71]. The surgical procedure has improved from transverse venotomy to 
percutaneous delivery. Dotter first suggested percutaneous delivery of venous valves [72] 
in 1981, though it was not successfully executed and reported until 2000 [58, 61]. 
 
The preceding list provides a relatively thorough literature review, yet developing a 
historical timeline of medical devices is limited due to the proprietary nature of the 
industry. For instance, in 1991, Baxter reported the development of a hydraulic mock 
circuit that accurately mimicked natural venous flow; however, the paper does not 
describe the venous valve [73]. Also, other surgeons have implanted venous valves 
provided by companies into the iliac and jugular veins of sheep, yet the venous valves are 
proprietary; and therefore the study results are not available. 
 
The preceding studies failed due to either in vivo thrombosis or biocompatibility 
problems. For instance, the umbilical vein valves and pellethane valves by Hill et al. all 
failed due to occlusion [51]. The three-month non-patent mechanical valves by Taheri et 
al. failed due to severe thrombotic occlusion. Two-thirds of the autogenous venous valves 
by Rosenbloom et al. failed from complications arising to thrombosis [56]. Partial 
thrombosis appeared in the valve cusps of the polyetherurethane valves by Uflacker [57]. 
Thrombosis occurred immediately after deployment of the gluteraldehyde-fixed bovine 
external jugular by Gomez-Jorge et al. [58]. Histology revealed that thrombosis was the 
cause for all non-patent valves in the PVVB study by de Borst et al. [59]. 
Biocompatibility was the primary concern for Taheri et al. and Gomez-Jorge et al. 
The two-year non-patent mechanical valves by Taheri et al. failed due to dense in-growth 
of intimal hyperplasia which rendered the valves functionless. The gluteraldehyde-fixed 
bovine external jugular by Gomez-Jorge et al. produced a granulomatous response and 
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foreign body reaction [58]. Biocompatibility and thrombus formation were the two failure 
causes in the animal studies.  
 
Prosthetic Vein Valves: Clinical Trials 
Prosthetic vein valves have been presented in two case studies; including, the second 
generation bioprosthetic venous valve (SG-BVV) trials [64], and the percutaneously 
delivered venous valve bioprosthesis (PVVB) trials [74].  
 
A first generation BVV was evaluated in three patients [64]. The first generation BVV is 
shown in Figure 15. The first patient received the implant in the femoral vein, at twelve 
months the leg ulcers had healed and edema was improved; though, the valve leaked 
when Valsalva was applied. The second patient received an oversized BVV in their 
femoral vein. This valve was patent and competent at 12 months, though clinical 
symptoms and disability scores did not improve. The valve tilted in the femoral vein of 
the third patient, though minimal leakage was present at 12 months, leg pain decreased 
and the valve continued to function with minimal leakage. The SG-SVV bioprosthesis 
was revised to include a modified stent to prevent tilting, as shown in Figure 17. SG-
BVV clinical trials are planned. 
 
Patent rights of the PVVB belong to Venpro Inc. (Irvine, California). The phase one 
PVVB valves were implanted into fifteen patients between 2001 and 2002 [75], the 
clinical results of two patients are reported by Gale et al.[74]. The valves were inserted 
into the mid-thigh femoral vein, via a right internal jugular vein puncture, as illustrated in 
Figure 18. Percutaneous deployment was successful in both patients. The first patient’s 
prosthetic was both patent and competent. However, complications with the prosthetic 
valve developed and the following treatments were necessary to prevent undo pain for the 
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patient. The treatments included ligation and stripping of the left saphenous vein after 12 
months, a 2 month course of nanocrystalline silver, firm compression dressings, and skin 
grafts. The patient was free of discomfort, though this successful outcome can not be 
attributed to the valve alone, as other medical interventions were used. The second 
patient suffered from post-insertion thrombosis, and multiple secondary procedures were 
performed to restore valve patency and competent. This clinical trial does not 
demonstrate the effectiveness of the PVVB, as both patients required multiple post-
operative procedures. The PVVB was redesigned by replacing the bovine jugular venous 
valve with pericardial tissue, increasing the radial stiffness of the Nitinol stent, and 
incorporating a heparin coating. The second generation PVVB is displayed in Figure 19; 
phase II clinical trials are planned in Europe and the U.S.A. For the reader’s information, 
phase I is an initial safety evaluation; whereas, Phase 2 Clinical trials determine the 
effectiveness of the product, and associated side effects and risks. 
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Blood is a fluid connective tissue with plasma as its matrix [76]. Plasma makes up 46-
63% of the blood volume. Plasma has a higher density than water since the plasma 
proteins are in solution rather than forming insoluble fibers like those in other connective 
tissues. Three formed elements (37-54% of blood volume) are suspended in the plasma, 
they include red blood cells (erythrocytes), white blood cells (leukocytes), and platelets 
(thrombocytes). The distribution by volume of formed elements is 99.9% erythrocytes, 
and a combined 0.1% for leukocytes and platelets. 
 
Platelets may be considered the smallest blood cells, though like RBCs they do not have a 
nucleus. They play a major role in blood clotting. The role of platelets is to stop bleeding 
at an injury site; they accomplish this by swelling, clumping together, and forming a 
sticky plug. Platelets will activate in high shear environments [77], sites of vessel injury, 
and when exposed to non-biocompatible medical implants. Vessel injury and non-
biocompatible medical devices trigger an inflammatory response, where the platelets 
adhere to the exposed collagen and localized fibulin and fibrinogen [78]. 
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Blood by Species 
Porcine whole blood may act like human blood for intravascular thrombosis. The platelet 
count in the porcine model is higher than the platelet count in humans; therefore, porcine 
blood may be more likely to coagulate under flow conditions. If the model can be proven 
in the porcine model, then the vein valve may be successful in a human. The composition 
of blood by species is listed in Table 2. The blood composition of ovine is also listed, 
because an ovine animal trial is planned. Ovine blood also has a higher platelet count 
than humans; and will therefore provide strong thrombotic potential results when 
considering a clinical trial. 
 
Table 2: Composition of blood by species and cell type [71, 76] 
Species Erythrocytes Leukocytes Platelets 
Human  Male 4,600,000 - 6,200,000 /µL 
              Female 4,200,000 - 5,400,000 /µL 
4,500 - 11,000 /µL 140,000 - 450,000 /µL
Porcine 5,000,000 - 8,000,000 /µL 11,000 - 22,000 /µL250,000 - 850,000 /µL
Ovine 9,000,000 - 15,000,000 /µL4,000 - 12,000 /µL 250,000 - 750,000 /µL
 
Blood Viscosity 
Viscosity is a measure of the resistance of a fluid to deform under shear stress.  
Whole blood has a viscosity of 3 to 4 centipoises depending upon hematocrit, 
temperature, and flow rate [79]. The viscosity of plasma is about 1.8 times the 
viscosity of water at 37°C, and is related to the protein composition of the plasma. As 
hematocrit increases, there is a disproportionate increase in viscosity. As temperature 
decreases, viscosity increases.  Viscosity increases approximately 2% for each degree 
Celsius decrease in temperature. The flow rate of blood also affects viscosity.  At 
very low flow states the blood viscosity increases, due to cell-to-cell and protein-to-
cell adhesive interactions that can cause erythrocytes to adhere to one another and 
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increase the blood viscosity. An acceptable average measure of viscosity for blood is 
3.5 centipoises. 
Biocompatibility of Poly(Vinyl) Alcohol (PVA) 
 
PVA hydogels have been used for numerous biomedical and pharmaceutical applications; 
such as, contact lenses, linings for artificial organs, development of artificial cartilage, 
vocal cords, drug delivery, soft tissue replacements, catheters, artificial skin, and 
hemodialysis membranes [80]. The biomedical advantages of PVA hydrogels include 
non-toxicity, non-carcinogenicity, bioadhesive characteristics, ease of processing, and 
shape-memory properties. 
 
Peppas and Merrill conducted some of the earliest work on PVA hydrogels as a 
biomaterial, in 1977 [81, 82]. The gels were examined for their blood compatibility and 
elastic behaviors. These researchers further investigated the possible reconstruction of 
vocal cords and bio-membranes in artificial kidney applications. 
 
Biocompatibility of PVA was investigated by Tamura et al. in 1986 [83]. The 
characteristics of the gel resembled those of natural tissue, ant these characteristics were 
not affected after long term implantation. Subcutaneous or intramuscular implantations in 
rabbits showed good bioinertness. Despite initial presence of inflammatory cells, they 
disappeared within two weeks of implantation and showed no adhesion to surrounding 
tissues. They concluded that the material would be useful be clinically useful. 
 
One cause of vessel trauma is the implantation of percutaneous devices; therefore, an 
inflammation reducing drug could be incorporated into the PVA matrix to reduce or 
prevent inflammation. PVA gels have been extensively investigated in terms of their 
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diffusive characteristics. Peppas and collaborators analyzed drug and protein diffusion 
[84]; and in another study investigated the transport of oxygen across a PVA membrane 
[85]. 
Relevant Previous PVA Vein Valve Results 
The PVA vein valve was previously evaluated for patency, competency and cyclic life 
[86]. The valve withstood 300 mm Hg of backpressure with less than 0.3 mL leakage per 
minute, demonstrated a bust pressure of 530 ± 10 mm Hg , opened with a pressure 





METHODS: THROMBOTIC POTENTIAL 
Experimental Design 
The purpose of this work was to evaluate the thrombotic potential of the PVA vein valve 
in a bench-top analysis. A flow system with venous flow conditions was designed and the 
PVA valves were attached to this system. Two flow systems were utilized, the initial flow 
system design was modified from a system previously designed in our lab [2], the second 
flow system utilized a pulsatile pump to imitate the venous pulsatile environment. 
Valve Manufacture 
The PVA valves were manufactured according to the procedure outlined in “Design and 
Development of a Novel Implantable Prosthetic Vein Valve”, by Rahul Sathe. The valve 
material was a 15% poly(vinyl-alcohol) hydrogel, manufactured per U.S. Patent 
5,981,826. The valves were fabricated by injecting PVA into a two-part silicone cavity 
mold, and subjecting the valves to a freeze-thaw curing process. The curing process 
consisted four 12-hour freeze periods intermittent with three 6-hour thaw periods. The 
valve orifice was then cut open with a two-sided surgical blade (no. 11, Miltex, York, 
PA) by placing the blade tip at the center of the orifice and applying pressure down 
through the orifice to separate the leaflets with one slice, thereby reducing the jagged 
edges associated with cutting the orifice with scissors. 
 
Blood Collection 
Fresh blood was collected from an abattoir (Holifield Farms, Covington, GA). Whole 
blood samples of approximately 1000 mL were harvested from pigs and quickly anti-
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coagulated with 1000 USP units/mL porcine heparin (Elkins-Sinn Inc. Cherry Hill, NJ) at 
6.0 ± 0.2 U/mL. The samples were transported to the laboratory in an insulated container, 
to limit temperature fluctuations during transport. The blood was able to drop in 
temperature from 37 ۫C (body temperature) to 20 ۫C (room temperature). In the laboratory, 
the collection time, volume, heparin condition, and presence of aggregates was recorded. 
Samples free of bubbles and aggregates were selected for experimental processing. The 
selected sample was mixed with a nutating rocker (Shelton Scientific) at approximately 
42 rpm for 15 minutes prior to the experiment. Experiments were completed within eight 
hours of harvesting the blood and conducted at room temperature. 
 
The heparin dosage was intentionally low compared to clinical heparin dosages, as this 
increases the likelihood of in vitro thrombosis. In vitro human donated blood experiments 
testing the deposition of platelets on collagen or under stasis conditions have used 
heparin dosages of 10 U/mL and 20 U/mL (LMWH) [87-89]. In an ex vivo porcine study, 
low levels of heparin (1.37 ± 0.036 U/mL) did not significantly affect platelet deposition 
[90]; therefore, the low heparin dosages used in the blood collection for this thesis should 
minimally affect platelet deposition. A heparin concentration of 6.0 ± 0.2 U/mL was 
selected based on previous in vitro analysis [2]. 
Non-pulsatile Model 
The flow system was modified from a one-pass, flow-through thrombosis assay using 
whole blood [2]. 250 mL of fresh, whole, porcine blood with heparin (6.0 ± 0.2 U/mL) 
was transferred into a blood donor collection bag (Pall Corporation, East Hills, NY). The 
collection bag was raised 30 cm above the test section, rotated on an orbital mixer 
(Labnet Int., Woodbridge, NJ), and attached to 90 cm of vinyl tubing (3mm inner 
diameter), followed by a 3-way valve, a pressure tap and the test section.  Pressure 
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upstream of the vein valve was recorded with a pressure transducer (Harvard Apparatus, 
South Natick, Massachusetts) and the flow rate was calculated from measurements with a 
graduated cylinder and a stopwatch. The experiment proceeded until flow cessation or the 
contents of the fluid reservoir were emptied. The flow set-up is illustrated in Figure 20 
and Figure 21. 
 
Figure 20: Diagram of non-pulsatile flow set-up 
 
 
Figure 21: Non-pulsatile flow set-up 
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Pulsatile Model 
The flow system was modified from a one-pass, flow-through thrombosis assay using 
whole blood [2]. This pulsatile system was designed to mimic the physiologic flow 
conditions present in the lower extremity venous system. During normal walking, calf 
compression propels 10 to 20 mL of blood through the veins, and compression occurs 
about 40 times a minute (0.67 Hz) [23, 25]. In accordance to previous in vitro studies 
performed, a blood collection time of at least 20 minutes was selected; as this provides 
enough time for thrombus to form [2]. Taking the frequency and time into consideration, 
the pulsatile pump was set to 0.75 Hz. Since there are three journal bearings across the 
circumference of the pump head, each revolution of the pump head accounts for three 
expansions and contractions of the tube. For instance, one revolution of the pump head 
took 4 seconds, so the frequency of the pump was 3 cycles / 4 seconds = 0.75 Hz. Fresh, 
whole, porcine blood with heparin (6.0 ± 0.2 U/mL) was transferred into a blood donor 
collection bag (Pall Corporation, East Hills, NY). The collection bag was raised 30 cm 
above the test section, rotated on an orbital mixer (Labnet Int., Woodbridge, NJ), and 
attached to 90 cm of vinyl tubing (3 mm inner diameter), followed by a 3-way valve, a 
pressure tap and the test section.  Downstream of the test section, a 50 cm segment of 
tubing (3.5 mm inner diameter) was passed through a Masterflex pulsatile pump (Model 
7520-25, Cole Parmer. Co, Chicago, IL) rotating at a frequency of 0.75 Hz. Pressure 
upstream of the vein valve was recorded with a pressure transducer (Harvard Apparatus, 
South Natick, MA) and the flow rate was calculated from measurements with a graduated 
cylinder and a stopwatch.  The experiment proceeded until flow cessation or the contents 














The test section included a vein valve, a flexible venous-like tube, and suture material. 
The vein like tube was manufactured from the PVA hydrogel, described above. The valve 
was inserted into the flexible tube and tightly tied in place to prevent blood from passing 
between the valve and the vessel wall. The flexible tube was further attached to the vinyl 
tubing by securing it with suture. 
Dacron Positive Controls 
A different positive control was used for each the non-pulsatile and pulsatile experiments. 
A positive control reveals that a procedure works according to expectations; in the blood 
flow experiments, this refers to a system that can form thrombus. A Dacron sleeve was 
constructed for the non-pulsatile experiments. The Dacron sleeve did not effectively 
mimic the PVA valve as a positive control, as the sleeve manufacturing was dependent 
on sewing techniques and the downstream opening was not a consistent size. Therefore a 
Dacron lined valve was constructed for the pulsatile experiments, where the geometry 
directly imitated the PVA valves. 
Dacron Sleeve 
A Dacron sleeve was constructed out of a polyester blend material, suture and a steel 
wire. The wire was bent into a 10-12 mm loop. The polyester was wrapped around the 
wire so that the material edges were positioned on the outside, it was then sewn to create 
a cone shaped sleeve, with a 10 mm opening upstream and 1 mm opening downstream, as 




Figure 24: Dacron Sleeve 
 
Dacron Lined Valve 
A Dacron lined valve was constructed from a cardiovascular Dacron patch (Hemashield 
Finesse, Boston Scientific Co., Oakland, NJ), suture and a PVA valve. Two same size 
pieces of Dacron were sized to fit from the top of the upstream side, through the orifice, 
to just beyond the edge of the leaflets downstream. The approximate Dacron size was 14 
mm ± 1 mm by 9 mm ± 0.5 mm. One stitch was placed on each Dacron piece on the 
upstream side, these sutures held the Dacron against the PVA valve. A Dacron lined 
valve is illustrated in Figure 25. 
 
 





Opening Pressure Test 
Opening pressure was measured by applying distal pressure on the valve and reading the 
pressure when water was visible downstream of the leaflets. A syringe was attached to a 
three-way valve with the test section and the pressure transducer (Harvard Apparatus, 
South Natick, MA); downstream the test section was open to atmosphere, as seen in 
Figure 26. The vein valve was orientated such that the distal end of the valve was closest 
to the syringe, and the proximal end was facing the ambient atmosphere. The test section 
was secured to the system with suture. Pressure was applied with the syringe and the 
valve was monitored for water collecting on the proximal side of the leaflets. The 
pressure indicated on the transducer when water collected downstream was recorded as 
the opening pressure for that valve. 
 
Figure 26: Opening Pressure Test set-up 
 
Backpressure Test 
Reflux leakage was measured by applying proximal pressure on the valve and reading the 
pressure when water was visible downstream of the leaflets. A syringe was attached to a 
three-way valve with the test section and the pressure transducer (Harvard Apparatus, 
South Natick, MA); downstream the test section was open to atmosphere, as seen in 
Figure 27. The vein valve was orientated such that the proximal end of the valve was 
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closest to the syringe, and the distal end was facing the ambient atmosphere. The test 
section was secured to the system with suture. Pressure was applied with the syringe and 
the valve was monitored for water collecting on the distal side of the leaflets. Pressure 
was measured up to 100 mm Hg, as to prevent valve failure. The pressure indicated on 
the transducer when water collection was observed was recorded as the backpressure for 
that valve.  
 
 
Figure 27: Backpressure test set-up 
 
Histology 
Samples were fixed in 10% formalin (VWR International, West Chester, PA) for at least 
72 hours. Formalin fixes at 1mm/day; in the thickest area, the sample was approximately 
2mm; therefore, 72 hours was sufficient. Samples were processed and embedded in 
paraffin. Deformation of the samples during processing was expected to be between 30 to 
50%. Samples were cut into 5-micron thin circular cross-sections, oriented perpendicular 
to flow. Eight sections from orifice areas, leaflet contact areas, were collected from each 
sample. Even numbered samples were stained with Haematoxylin and Eosin stain (H&E), 
and odd numbered samples were stained with Carstair’s stain. Sections were 
microscopically analyzed using a Nikon E600 microscope, a digital camera and Q-
capture software. Three magnifications were captured: 4x, 10x, and 20x. 
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H&E Stain 
H&E stain is the most widely used stain in medical diagnosis, it stains for basophilic and 
eosinophilic structures. H&E stain was prepared using a standard program in the auto-
stainer (Leica AutoStainer XL, Wetzler, Germany). The procedure included three 
changes of Xylene Substitute; two changes of 100% alcohol; water washes intermittent 
with exposure to Hematoxylin, acid alcohol, Scott’s, and Eosinl; followed by three 
changes of alcohol; and two changes of Xylene substitute. The following structures may 
be identified: nuclei (blue); erythrocytes and eosinophilic granules (bright pink to red); 
and cytoplasm and other tissue elements (various shades of pink). 
Carstair’s Stain 
Carstair’s Stain is used to detect fibrin and platelets in clotted blood or thrombus. 
The Carstair’s Stain procedure was obtained from Sheehan’s Theory and Practice of 
Histotechnology [91]. The samples were deparaffinzed and rehydrated in distilled water. 
To mordant, 5% ferric alum was exposed to the sections for 10 minutes and rinsed in tap 
water. To stain, Harris’ hematoxylin was exposed for 5 minutes, rinsed in tap water, and 
then exposed to picric acid-orange G solution (80 mL saturated picric acid, 320mL 
isopropanol, 0.8g orange-G) for 20 minutes (up to 1 hour). The sections were then rinsed 
in distilled water and stained in ponceau fuchsin (2.0g acid fuchsin, 2.0g pnceau 2R, 4mL 
glacial acetic acid, 396mL distilled water) for 5 minutes. To differentiate, the sections 
were exposed to 1% phosphotungstic acid for 2 minutes, and then rinsed well in water. 
The final staining was to expose the sections to aniline blue solution (4.0g aniline blue, 
400mL 1% acetic acid) for 10 minutes. Samples were rinsed in distilled water, 
dehydrated, and mounted. The following structures may be identified: fibrin (red), muscle 





RESULTS: THROMBOTIC POTENTIAL 
Non-pulsatile Blood Flow 
The non-pulsatile flow system was designed to impose a constant upstream pressure of 
blood on the test section, similar to the pressure in the venous system. Blood was 
perfused through 7 PVA valves; flow was established for all test sections. The flow 
profile refers to the collected blood volume over time, which was plotted in terms of 
milliliters per minute. The upstream pressure over time was recorded in millimeters of 
mercury and plotted with their corresponding blood volume graphs. All 7 PVA valves 
demonstrated significantly different flow profiles, as illustrated in Figure 28 through 
Figure 34. The flow profiles presented in Figure 28 through Figure 34 illustrate both the 
volumes collected and the pressure fluctuations over time. Valves 1, 5, 6, and 7 produced 
very little flow, none of them ever passing more than 23 mL of blood through the valve 
orifice, the upstream pressures were relatively constant at 24, 21, 21, and 23 mmHg, 
respectively. The limited flow could have been attributed to the pooling of blood 
downstream of the valve, since the valve was naturally in a closed position, it is 
hypothesized that stagnant blood collected upstream of the leaflets. Valve 2 produced an 
“S” shaped profile with a gradual cessation of flow; the pressure remained fairly constant 
around 24 mmHg. Valve 3 had a reasonably constant flow with exhaustion of blood at 
32.5 min; the pressure measurements fluctuated between 17 to 20 mmHg. Valve 4 was an 
interesting case where the flow rate increased and decreased throughout the run. Periodic 
adjustments of the blood bag would initiate the sudden increase in flow. The pressure 
would spike just prior to the flow increasing, indicating that an increase in pressure 
would re-establish flow. Pressure measurements varied between 10 to 19 mmHg 
throughout the run. All valves were photographed before and after attachment to the 
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apparatus, as presented in Figure 35. Figure 35 illustrates a valve prior to placement in 
the apparatus where the orifice is intact and clean; also, a valve after removal from the 






































































































































































































Figure 34:  Non-pulsatile flow of porcine blood through PVA valve 7 
 
  
Figure 35: PVA valve (A) prior to placement, and (B) after placement in the non-pulsatile blood 
system 
 
Visual confirmation that blood was flowing through the valve, as opposed to around the 
valve, was accomplished by noting no visible blood between the valve and the PVA tube, 
as seen in Figure 36. Upstream and downstream of the valve the tube appeared red; 
though, at the valve location the tube appeared white, since at this location the PVA valve 
was flush with the PVA tube. 
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Figure 36: Close-up of test section in non-pulsatile system 
 
A Dacron sleeve was placed in the flow set-up as a positive control. The Dacron sleeve 
for both before placement and after removal from apparatus is illustrated in Figure 39. As 
a positive control, the Dacron should have occluded the system faster, compared to the 
PVA valves. Two Dacron sleeves were evaluated and both demonstrated very different 
flow profiles, as illustrated in Figure 37 and Figure 38. Dacron sleeve 1 produced very 
little flow, never passing more than 24 mL through the valve orifice, the pressure 
upstream was a constant 24 mmHg. Dacron sleeve 1 acted very similar to valves 1, 5, 6, 
and 7. Dacron sleeve 2 started with a fairly steep flow profile, though there was a gradual 
cessation of flow at 25 min. The flow of Dacron sleeve 2 behaved similar to valve 3, 
though the pressure profiles were different. Dacron sleeve 2 had a gradual increase in the 
pressure as the flow started to slow; whereas the upstream pressure on valve 3 did not 
modulate in unison with the flow. The Dacron sleeves were not identical, as the 
construction was variable due to sewing technique. The flow profile variations could 
possibly have been caused by the construction variability. A Dacron sleeve attached to 
the flow set-up is illustrated in Figure 41. The polyester material bulked on the exterior of 
the metal ring, and when placing the Dacron sleeve inside the vein like tube it would 
distend the tube. Regardless, the upstream inside diameter was 10 mm ± 1 mm, which is 
consistent with the PVA valves. The material composition of the polyester was not 






information was not available. This unknown material content could have attributed to 
the unexpected flow profile of Dacron sleeve 2. Evident from the non-reproducible 
results of the PVA and Dacron flow profiles, the Dacron sleeve did not successfully 
perform as a positive control. A summary of the flow profiles of all PVA valves and 
Dacron sleeves are illustrated in Figure 40. This system did not provide a consistent flow 



























































Figure 38:  Non-pulsatile flow of porcine blood through Dacron Sleeve 2 
 
 
    
Figure 39: Longitudinal View of Dacron Sleeve (A) prior to blood flow exposure, and (B) after blood 
flow exposure. Cross-sectional View of Dacron Sleeve (A) prior to blood flow exposure, and (B) after 



























Figure 40: Non-pulsatile flow through PVA valves and Dacron Sleeves 
 
 
Figure 41: Dacron sleeve attached to non-pulsatile system 
 
Pulsatile Blood Flow 
Blood was perfused through five PVA vein valves. All five valves remained patent after 
20 minutes of blood flow without significant flow rate deterioration.  A patent valve 
attached to the pulsatile blood set-up is shown in Figure 50. The flow rates and 
corresponding pressure measurements for each valve and Dacron lined valves are shown 
in Figure 42 through Figure 49. PVA valve 1 through 5 all produced the same volume 
flow profiles, though their pressure profiles are slightly different. The range on each 
pressure measurement point corresponds to the stop and start of flow from the pulsatile 
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pump. The pressure for PVA valve 1 is between 13 – 15 mmHg, this is low compared to 
all other PVA valves. The pressure range for valves 2 through 5 is 15 – 21 mmHg. Once 
the system was exhausted of blood the pressure dropped off to just above 10 mmHg, it 
did not drop further since the system was not airtight. All Dacron lined valves displayed a 
gradual cessation of flow. The Dacron lined valves, 1 through 3, passed 35, 83, 104 mL 
of blood prior to cessation of flow at 2, 7, and 9 minutes, respectively. The pressures 
fluctuated until flow cessation, where they then produced a relatively constant pressure 




















































































































































































































































Figure 49: Dacron Lined Valve 3, blood volume collection and pressure fluctuation measurements 
 
 
Figure 50: Test section with patent valve. 
 
The average blood flow rate of 11.8 ± 0.4 mL/min through the valves remained constant 
for greater than 20 minutes, as shown in Figure 51. There was no gross thrombus visible 
on any of the valve leaflets.  The leaflets remained functional and the valves remained 
competent against backpressure. When the flow system depleted the blood reservoir the 
roller pump tried to suck blood through the valve, the entire valve would collapse due to 



























Figure 51: The PVA valves produced a constant flow rate; whereas, the Dacron lined valves 




Figure 52: Test section with a patent valve, though the reservoir of blood was exhausted and the 
pulsatile pump was still trying to draw blood. 
 
The Dacron lined valves initially produced the same velocity profiles as the PVA valves; 
though, they did not remain patent for the experiment, but rather occluded completely.  
The flow rate reduced after two to eight minutes into the perfusion. On average, the 
polyester valves occluded after 6 ± 3.6 min of perfusion. The frequency of occlusion for 
the polyester valves in this assay was significant to p<0.02. 
 
The occluded valve created an unmistakable visible image as the roller pump tried to 
suck blood through the valve.  With occlusion, the flexible tube collapsed violently 
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instead of the valve reopening.   Thus, the system was a severe demonstration of the 
adherent nature of the occluding thrombus. A test section containing a collapsed 
downstream test section is shown in Figure 53. After removing the Dacron valves from 
the flow system, the polyester fibers were covered with blood and were visibly matted 
down, as seen in Figure 54.  After occlusion, some red clot remained in the lumen of the 
tubes. The Dacron lined valve was preserved for histological analysis. 
 
Figure 53: Test section containing a Dacron lined valve, the downstream section is collapsed due to 








The Student’s t-test was used to compare the time to occlusion between the PVA valves 
and the Dacron lined valves were statistically different. The p-value was 0.02. The time 
to occlusion for the PVA valves was assumed as >20 min, as seen in Table 3. The time to 
occlusion for the Dacron lined valves was averaged as 6 min, as seen in Table 3. The t-
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statistic was 6.73, and the two tailed t-critical was 4.30. With a 98% confidence, the time 
to occlusion of the PVA valves versus the Dacron lined valves were statistically different. 
 
 

















The pulsatile flow system was designed to test the thrombotic potential of the PVA valve, 
to eliminate the possibility that the Dacron leaflets would stick to each other in a non-
blood environment. The Dacron cardiovascular patch is designed to readily attach to host 
tissues; therefore it is reasonable to assume it might attach to itself in a flow environment.  
An inert solution with the same viscosity as blood was perfused through the system. A 
20% glycerine solution in water created a viscosity similar to blood, of 3.5 centiPoise. 
This solution was perfused through the pulsatile system with the PVA valve and 
subsequently the Dacron lined valve. The average flow rate of both the PVA valve and 
Dacron lined valve was 10.2 mL/min, as seen in Figure 55. Both the PVA valve and the 
Dacron lined valve developed similar flow profiles; therefore, the cessation of flow in the 


























Histology was performed on both the PVA and Dacron lined valves to identify cell 
accumulation and the cause for Dacron cessation of flow. The histology stains utilized 
were Haematoxylin and Eosin stain (H&E), and Carstair’s stain (specific for platelets). A 
pictorial representation of how the PVA vein valve appears after histological processing 
is depicted in Figure 56. The appropriate centimeter magnification scales are depicted in 
Figure 57. A representative sample of the H&E staining is found in Figure 58 for a 
Dacron lined valve, and in Figure 59 for a PVA valve. A representative sample of the 
Carstair’s staining is found in Figure 60 for the Dacron lined valve, and in Figure 61 for 
the PVA valve. As the PVA was processed the leaflets shrank; and therefore, they 
appeared separated on the histological stains. As can be seen in the PVA valve slides, 
there was no cellular accumulation on the PVA valves.  
 
The PVA material is represented as pink in the H&E stain and a faint blue-grey in the 
Carstair’s stain. With regard to the Dacron lined valve slides, the gray circular structures 
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represented the Dacron fibers. The red debris located between the Dacron leaflets 
represented the cellular material that was preventing blood from passing through the 
leaflets in the in vitro model. Further analysis with Carstair’s stain reveals that platelet 
aggregation was a key component in the red debris. The presence of platelets on the 
Dacron leaflets, and the complete absence of platelets on the PVA valves confirmed that 
the pulsatile blood flow set-up had the potential to thrombose, yet the PVA valves do not 
clot in this system.  
 
Figure 56: Pictorial representation of the shrinking effects of histological processing on the PVA vein 
valves; left, profile prior to processing; right, profile after processing. 
 
   
Figure 57: Centimeter magnification scales for histology images; (A) 4x, (B) 10x, and (C) 20x.
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Figure 58: H&E Staining of Dacron lined valves; (A,B,C) valve 1, (D,E,F) valve 2; magnifications of 




   
Figure 59: H&E Staining of PVA valve surfaces, magnifications of (A) 4x, (B) 10x, and (D) 20x. 
 






A B C 
D E F 
 66
   
 
   
Figure 60: Carstair’s Staining of Dacron lined valves, (A,B,C) valve 1, (D,E,F) valve 2 
magnifications of (A,D) 4x, (B,E) 10x, and (C,F) 20x. 
 
   
Figure 61: Carstair’s Staining of PVA valve, magnifications of (A) 4x, (B) 10x, and (C) 20x. 
 
Shear Rate 
The shear force required to activate platelets can be estimated as 4 x 105 Ns/m2, which is 
derived from equation 1. The shear force present in the orifice of the prosthetic vein valve 
is 1.9 x 10-3 Ns/m2. Reynolds number for the prosthetic vein valve was 134. The shear 
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CHAPTER 4 
METHODS: DELIVERY SYSTEM DESIGN 
Experimental Design 
Analysis was performed to design a percutaneous delivery system for the PVA valve. The 
valves were tested for their compressibility and plastic deformation by compression time. 
Maximum PVA valve compression time was determined and appropriate stents, catheters 
and sheaths were selected to complete the delivery system. 
Radial Compression (Long Term) 
The PVA valves were inserted into balloon expandable stents, and a balloon catheter was 
placed through the orifice so that the balloon protruded from each end of the stent, as 
seen in Figure 62. The PVA valve was sutured to the stent and collapsed by applying 
pressure with rolling the stent between the forefinger and thumb. Placing a slipknot with 
string around the stent and tightening the knot further compressed the stent. The stent-
valve-catheter system was maintained in the compressed state for 2 weeks, and then 
expanded through balloon catheter expansion. The degree of plastic deformation was 
visually evaluated. 
 





To identify how long the valves may be placed under compression and not experience 
plastic deformation, 3 valves were analyzed in a flat compression experiment. The valves 
were initially evaluated for opening pressure and backpressure conditions. The valves 
were not exposed to a backpressure beyond 100 mm Hg to prevent valve damage.  The 
valves were photographed. The PVA valves were then placed between two cover slides 
and flattened with the orifice in the open position, as seen in Figure 63 and Figure 64. 
Three valves were compressed for 2 hours, while immersed in water; removed from 
compression; and returned to a water bath for 15 minutes to allow for re-expansion. The 
valves were photographed and evaluated for opening pressure and backpressure 
conditions. The same valves were subsequently re-compressed for 4hrs, 6hrs and 9hrs, 
and re-evaluated. To provide the valves additional time to fully relax back to their 
original configuration the uncompressed valves were placed in water for 12 hours and re-
evaluated. 
 
Figure 63: Flat compression of vein valve 
 
 
Figure 64: Flat compression of vein valve, emphasizing the open orifice 
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Radial Compression (Short Term) 
The PVA valves were inserted into balloon expandable Palmaz-like stents, 10mm 
diameter and 20-25mm in length, (Cordis Endovascular, Miami, FL; and 
IntraTherapeutics, St. Paul, MN), and sutured into place. The initial stent-valve diameter 
was recorded. The valves were evaluated for opening pressure and backpressure. A 
balloon catheter (10 mm balloon diameter, Express Billiard LC, Boston Scientific, 
Natick, MA) was placed through the orifice, so that the balloon protruded from each end 
of the stent. The valves were crimped with an HH100 PTCA R&D Handheld Crimping 
Tool (Machine Solutions Inc., Flagstaff, AZ) to 100 lbs. of force, as seen in Figure 65. 
The crimping tool is shown in Figure 66. The crimped diameter was recorded. The valves 
were immersed in water for 1 hr or 2 hrs. A 10 mL syringe (Becton Dickinson and Co, 
Franklin Lakes, NJ) was filled with 10 mL of air, attached to the end of the balloon 
catheter, and the air was injected into the balloon. The balloon was maintained expanded 
for 30 sec; following the air was removed and the catheter was removed from the valve 
orifice. The final diameter was recorded. The valves were immersed in water for 24 




Figure 65: Radially Compressed Valve and Stent on a balloon catheter 
 
 




RESULTS: DELIVERY SYSTEM DESIGN 
Stent Selection 
Stents are divided into two categories: self-expanding and balloon expanding. The self 
expanding stents are constructed from Nitinol (equal parts titanium and nickel), which is 
a shape-memory and superelastic material. A valve was inserted into a self-expanding 
stent and attempted to be crimp with commercial grade crimping machines from Machine 
Solutions Inc. The valve-stent system could not crimp, therefore the self-expanding stent 
was eliminated as an option at this time. 
 
Two classes of balloon-expanding stents were considered: open cell and closed cell. 
Balloon-expanding stents are typically constructed out of steel, and is therefore 
unfortunately not as flexible as the Nitinol stent. The open cell stent available was an 
Express biliary LD stent (Boston Scientific). The closed cell stent available was a Palmaz 
stent (Cordis). The open cell stent poorly expanded and contracted, leaving the stent 
struts deformed, as seen in Figure 67. These open cell stents had a specific open diameter, 
for instance an open diameter of 10 mm. As oppose to the Palmaz stent which had a 
range of open diameters, for instance 9 – 12 mm, making the Palmaz stent a more 
versatile design. The Palmaz stent expanded and contracted without strut deformation, as 
seen in Figure 68 and Figure 69. The Palmaz stent was selected as the most appropriate 
stent available based on the elimination of the Nitinol stents due to their crimping 
difficulties, the poor performance of the open cell stents, and the satisfactory performance 




Figure 67: Express Biliary LD stent (Boston Scientific) 
 
  




Figure 69: Top, Crimped Genesis Palmaz Stent. Bottom, Crimped Palmaz Stent 
 
Radial Compression: Short Term 
Valves were analyzed by radial compression with a handheld crimper; the results are 
presented in Table 4. The average initial outside diameter of the valve-stent system was 
8.8 mm ± 0.1 mm. Prior to compression exposure the valves demonstrated an opening 
pressure of 3 mm Hg ± 1 mm Hg, and a backpressure of 100 mm Hg. To prevent valve 
damage, the valves were not pressurized beyond 100 mm Hg. The average compressed 
outside diameter of the valve-stent system was 6.5 mm ± 0.1 mm. They were compressed 
for 1hr and subsequently expanded. Visually the expanded valves retained their original 
configuration, as illustrated in Figure 70. The valves exhibited an opening pressure of 4 
mm Hg ± 1 mm Hg and withstood a backpressure of 100 mm Hg. The average expanded 
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outside diameter of the valve-stent system was 9.5 mm ± 0.5 mm. All valves met design 
criteria of opening pressure below 5 mm Hg and a backpressure up to 100 mm Hg. 
 
Table 4: Results from Flat Compression Experiment 
 
  
Figure 70: Left, valve prior to radial compression; right, valve after 1 hr of radial compression and 
re-expansion. 
 
Complete Delivery System 
Based on the “Radial Compression: Short Term” results the maximum crimped diameter 
was used to select the appropriate sheath size. The diameter was converted to French with 
the conversion of 1 mm = 3 Fr. The sheath size was the corresponding French value. 
 
A sheath was selected that will fit the maximum crimped diameter of 6.5 mm ± 0.1 mm. 
The result is a complete delivery system including: a 20-25 mm long and 10 mm 
























(up to 100 mmHg)
1 8.8 4 100 6.48 1 9.9 5 100
2 9.0 2 100 6.40 1 9.9 3 100
3 8.8 3 100 6.50 1 9.0 3 100
4 8.9 3 100 6.50 2.5 9.5 3 100
5 8.6 2 100 6.43 1 9.0 5 100
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Valves were analyzed by flat compression. Prior to compression exposure the valves 
demonstrated an opening pressure of 3 mm Hg ± 1 mm Hg, and a backpressure of 100 
mm Hg. To prevent valve damage, the valves were not pressurized beyond 100 mm Hg. 
Subsequently at 2 hrs, 4 hrs and 6 hrs after compression the valves exhibited an opening 
pressure of 3 mm Hg and a backpressure of 100 mm Hg, as shown in Table 5. At 9hrs 
under compression, the prosthetics were deformed into an open orifice position, even 
after 15 minutes in an immersed non-compressed state. The valves were subsequently left 
in a water bath for 12 hrs and re-evaluated. After 12hrs in an immersed non-compressed 
state, the valves visually relaxed back to their original configuration, as illustrated in 
Figure 71, and exhibited an opening pressure of 3 mm Hg and a backpressure of 100 mm 
Hg. 
 
Table 5: Results from Flat Compression Experiment 
0 Hrs 2 hrs 4 hrs 6 hrs 9 hrs * 9 hrs **
1 4 3 3 3 0 3
2 3 3 3 3 0 3
3 3 3 3 3 0 3
1 100 100 100 100 0 100
2 100 100 100 100 0 100
3 100 100 100 100 0 100
Time
* tests performed 15 min after valves were removed from compression, valves did not have 
  enough time to relax back to their original configuration
** tests performed 12 hrs after valves were removed from compression, valves had enough time 
    to relax back to their original configuration
Back- Pressure (mm Hg)
up to 100 mm Hg




                 
 
                  
Figure 71: Visual deformation of valves after corresponding times of compression: A) control valve 
at 0 hrs of compression, (B) 2 hrs, (C) 6 hrs, (D) 12 hrs, (E) 18 hrs, and (F) 4 days. 
 
Radial Compression (Long Term) 
During stent crimping the stent became deformed, as is evident in Figure 62, though the 
valves were successfully reduced from 8 mm to 5 mm ± 1 mm.  Valves were visually 
analyzed after expansion to reveal a permanently open orifice, unmistakable creases in 
the exterior diameter, and expanded stent deformation. The PVA material plastically 
deformed from the long-term compression exposure, as shown Figure 72.  
  
Figure 72: Plastically deformed valves, after 2 week radial compression 






Evaluating the thrombotic potential of a prosthetic vein valve in an in vitro set-up is a 
novel process. The most common practice to test the thrombotic potential is in an animal 
model. In the “Prosthetic Vein Valves : Animal Studies” section the majority of studies 
failed due to in vivo thrombosis [51, 55-59]. They concluded that their valves had the 
potential to form thrombus in vivo. If they had performed an in vitro thrombosis potential 
study they might have saved time, money and animal lives. 
 
When designing an in vitro model it is most relevant for the model to be as close to 
physiologic conditions as possible. A potential draw-back to this in vitro set-up is that the 
flow through the prosthetic valves was 11.8 ± 0.4 mL/min, yet the blood flow through the 
femoral vein is around 70 mL/min. The flow was lower than physiologically observed 
valves because the frequency and collection time were selected, but the tubing diameter 
was restricted. The pulsatile frequency was chosen to mimic the normal walking cadence 
of 0.67 Hz. The tubing diameter could not be increased to reduce flow as it was limited to 
the pulsatile pump tubing specifications. Even though platelet adhesion in a stenosis 
happens at high velocities, vein thrombosis typically is thought to occur at low velocities. 
Therefore modeling a low flow rate may be more appropriate, since it is the 
physiologically worst case scenario. For instance, when one sits for a long period of time 
on a transatlantic flight and the calf pump is not actively engaged, the blood is traveling 
at a lower velocity back to the heart. 
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Histological analysis with H&E revealed that the red debris preventing blood from 
passing through the Dacron leaflets was cellular material. Further analysis with Carstair’s 
stain revealed that platelet aggregates were a key component of the red debris. The 
presence of platelets on the Dacron leaflets and the complete absence of platelets on the 
PVA valves confirmed that the pulsatile blood flow set-up had the potential to thrombose, 
yet the PVA valves do not clot in this system. A challenge faced when preparing the 
valve for histological analysis was that the fixation process shrank and deformed the 
valve, therefore the orifice was not occluded as the Dacron leaflets separated. However 
the presence of platelets on each leaflet was indicative of thrombosis. 
Delivery System 
Due to the plastic deformation revealed in the “Radial Compression: Long Term” results, 
it was concluded that compressing the GT vein valve for an extended period of time was 
not feasible, and alternative methods needed to be explored. The initial obstacle to 
address was determining how long the valves could remain compressed prior to 
experiencing plastic deformation; this lead to the flat compression experiments. The flat 
compression experiments revealed that the PVA material may be compressed for short 
periods of time, less than 6 hrs, without experiencing plastic deformation. Concurrently, 
it was discovered that the Edwards Life Sciences’ percutaneous heart valve, currently in 
clinical trials, is compressed at the surgical hospital just prior to implantation. Given the 
successful implementation of pre-procedure crimping, a similar technique was pursued 
for the GT vein valve to allow it to be compressed within 6 hours of implantation. 
Therefore an accurate and portable stent crimper was identified. The valves performed to 
specifications once expanded. The result is a complete delivery system including: a stent, 
a balloon catheter, and a sheath. 
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To provide minimal vessel trauma the sheath diameter for any percutaneous device needs 
to be as small as possible. It would be ideal to place the GT vein valve through a small 
vessel and up to the implant location. One significant disadvantage to the delivery system 
design presented is that the maximum crimped diameter is 6.5 mm ± 0.1 mm, which is 
large in terms of vessel size. The sheath required for this prosthesis is 20 Fr, which could 
not be placed from the saphenous vein up to the femoral vein. Therefore, the most 
appropriate route would be from the external jugular vein down through the heart to the 
femoral or iliac vein, as depicted in Figure 18. There would be additional stress on the 
heart when passing a catheter through the superior vena cavae to the inferior vena cavae. 
The GT vein valve is manufactured by an injection molded process; therefore, a second 
generation GT vein valve mold could easily be streamlined to reduce the valve profile 
and make the crimped diameter smaller. 
 
As currently designed the crimped valve diameter of 20 Fr is too large to implant into 
humans percutaneously. An appropriate percutaneous device is within 6 to 10 Fr. Future 
work should include the redesign of the valve to reduce the thickness of the cylindrical 
supporting material. 
 
Due to the flexibility of Nitinol, it is worthwhile to reconsider Nitinol stents as oppose to 
the selected steel stents. It was unfortunate that crimping limitations prevented the 
application of the Nitinol stent. As crimping technologies develop and through the re-
design of the valve prosthetic, a Nitinol stent is expected to be a more appropriate stent 
selection. 
Comparison to Previous Prosthetic Animal Valves 
The two most successful vein valve studies use acellular tissues: the SG-BVV study used 
porcine small intestine submucosa (SIS), and the PVVB study used gluteraldehyde-
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preserved bovine jugular valves. The GT vein valve is constructed from a synthetic 
polymer, which provides several advantages over SIS and gluteraldehyde-preserved 
bovine jugular valves. The PVVBs are fixed with gluteraldehyde, which is a toxic 
substance that will prevent cells from integrating into the material in vivo. This 
gluteraldehyde preservation process will cause a limited cyclic life due to the cross-
linking of the collagen fibers, and ongoing biocompatibility issues due to the 
gluteraldehyde toxicity. The SIS tissue appears to be an appropriate material for vein 
valve prosthetics, with regards to its biocompatibility. However, despite revisions to the 
SIS vein valve, the SG-BVV continues to experience in vivo tilting. Tilting would not be 
an issue with the GT vein valve because of the long axial dimension. In addition, GT vein 
valve is manufactured by injection molding; therefore, the valve can be mass produced 
and the design is easily modified. This is unlike acellular tissues which require extensive 
time to process the tissues and modification of the tissue valve design would create 
concerns regarding suturing locations and tissue to stent attachment sites. Another 
advantage is that PVA may be processed to include embedded drugs, which could 
promote cell growth and/or reduce thrombus formation. By designing the GT vein valve 
out of PVA it has superior biocompatibility and structural integrity, may be mass 
produced, and has the potential to utilize new drug delivery technologies. 
Future work: Animal Trials 
Performing an animal study will evaluate the biocompatibility of the GT vein valve. The 
low thromobotic potential of the GT vein valve has been confirmed in an in vitro 
analysis; therefore, the appropriate next step is to perform an animal study and confirm 
the vein valve’s biocompatibility. PVA has previously been used as a medical implant 
material therefore, biocompatibility is expected. 
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An ovine trial has been designed to test in vivo valve patency and quantify in vivo 
thrombotic potential. Five sheep will surgically receive implants for a duration of 4 
weeks. As an initial feasibility study, only a few animals will be used to gain insight into 
the performance of the valve.  Five animals will be used to account for potential biologic 
variance. Previous experimental studies have been performed on populations between 4-
10 animals [51, 52, 55, 56]. Four prosthetic vein valves will be implanted into each 
animal; one in each of the external jugular veins, and one in each of the iliac veins.  
Species Selection 
Ovine were chosen because their cardiovascular geometry and physiology is similar to 
human physiology and anatomy.  To test the patency of any valve, the hemodynamics 
and rheology of the animal should be as representative of humans as possible.  They are 
also the most common animal for vein valve studies. Sheep are also robust animals, 
recovering fairly quickly from surgical operations, and are fairly easy to handle. 
Surgical Procedure 
The prosthetic valves will be implanted via percutaneous delivery. The external jugular 
vein (EJV) will be exposed by a longitudinal incision.  To implant the valve, a sheath will 
be placed into the EJV.  The flexible valve will be placed into a sheath delivery system 
prior to the time of surgery.  The valve will be directed into the common iliac vein under 
fluoroscopic guidance. The valve will be deployed in this location with a balloon-
expandable stent mechanism.  The same procedure will be repeated for the EJV on the 
same side.  Placement of the PVA valve is demonstrated in Figure 73. The venotomy in 
the EJV will be closed with interrupted sutures. The same procedure will then be repeated 
in the other EJV in order to deliver an additional valve/stent mechanism into the common 






Figure 73: (Top) PVA valve positioned beside right external jugular vein.  
Bottom, PVA valve implanted into right external jugular vein. 
Imaging 
Patency will be demonstrated using two measurement techniques: venogram and Doppler 
ultrasound. A venogram consists of IV injection of iodine containing, radiopaque contrast 
media, followed by a fluoroscopic x-ray. The second method for demonstrating patency 





Animals will be sacrificed 4 weeks after implant, and segments of the external jugular 
veins and iliac veins containing the valves will be excised and examined with 
histomorphological techniques. A four week study is an appropriate study time to 
demonstrate biocompatibility. 
Study Outcomes 
Due to the low in vitro thrombotic potential and the long track record of PVA as a 
medical implant material, positive trial results are expected. In the event of negative 
biocompatibility results, the product design would be re-evaluated. In the case of positive 





Evaluating the thrombotic potential of a prosthetic vein valve in an in vitro set-up is a 
novel process, as the thrombotic potential is typically evaluated in an animal model. 
Animal studies require the long process of approval from animal care and use 
committees, the trials are costly, the study itself is time consuming, and animal lives are 
sacrificed. In vivo models are necessary to determine the biocompatibility of the 
prosthetic device, and an important step towards clinical trials; yet using an in vitro 
thrombosis model provides an appropriate intermediate step between valve development 
and in vivo analysis. 
 
The in vitro model presented perfuses whole porcine blood through a prosthetic vein 
valve. The pulsatile frequency of the system, 0.75 Hz, approximates the normal walking 
cadence of an adult. A Dacron lined valve provided an appropriate positive control to 
confirm the thrombotic potential of the system. This in vitro set-up was used to evaluate 
the GT venous valve. 
 
The GT venous valve demonstrates low thrombus formation in the perfusion system.  The 
GT vein valves remained patent after 20 minutes of perfusion with no adherent platelets 
of fibrin thrombus under histological analysis. In contrast, the control valves lined with 
polyester occluded after 6 ± 3.6 min of perfusion.  Histology revealed adherent fibrin, 
RBCs and platelets on the positive controls.  The time of occlusion for the Dacron lined 
valves in this assay was significant (p<0.02). The GT valve exhibited low flow resistance, 
strong competency, fatigue-resistance, low-thrombogenicity, and material flexibility. 
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Given the positive results from the in vitro evaluation, the GT vein valve has excellent 
potential. By choosing to manufacture the GT vein valve out of a synthetic material, 
PVA, it has outstanding structural integrity, may be mass produced, and is easily 
modified. Furthermore, PVA has demonstrated exceptional biocompatibility in a wide 
range of other medical devices and it has the potential to incorporate new drug delivery 
technologies. 
 
The future of medical implants lies in percutaneous devices; therefore, to create a 
marketable and less invasive implant, a percutaneous delivery system has been designed 
for the GT vein valve. As designed, this system will be utilized in an ovine trial of the 
valve. A stent will be placed around the GT vein valve and crimped onto a balloon 
catheter; it will then be loaded into a sheath. The profile of the collapsed valve is 6.5 mm 
± 0.1 mm, which indicates that a large vessel, such as the external jugular vein or 
common iliac, will be required for delivery. Reduction of the crimped valve profile will 
allow the valve to be delivered from smaller vessel locations, therefore a second-
generation GT vein valve should aim to reduce this profile. Future improvements could 
include embedding drugs into the PVA which would limit thrombosis, inflammation or 
foreign body response mechanisms. Due to the low in vitro thrombotic potential and the 
strong history of PVA as a medical implant material, positive trial results are expected.  
 
Providing relief to chronic venous insufficiency is a worth while pursuit as patients 
experience swelling, edema, pain, itching, varicose veins, skin discoloration, ulceration 
and limb loss. Current clinical therapies are only modestly effective; and therefore, a 
prosthetic vein valve can provide a cure for this debilitating disease. With successful 
animal and human trials this valve can provide a potential intervention for the 7 million 
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